ARS Pharmaceuticals Reports the EC’s Approval of Eurneffy (Adrenaline Nasal Spray) to Treat Type I Allergic Reactions
Shots:
-
Following the US FDA approval, the EC has approved Eurneffy (2mg) for type I allergic reactions (anaphylaxis) in adults & children (≥30kg). It will be available in Q4’24 through a pharmaceutical company
-
The approval was supported by the results from a study, involving ~1200 administrations among >700 subjects, along with studies and peer-reviewed literature supporting these results
-
The study assessed PK/PD of Eureffy (2mg) under various conditions such as single and repeat dosing, self-administration, pediatric dosing & in nasal conditions like congestion and rhinorrhea due to allergens or infections like cold/flu
Ref: ARS Pharmaceuticals | Image: ARS Pharmaceuticals
Related News:- ARS Pharmaceuticals’ neffy (Epinephrine Nasal Spray) Gains the US FDA’s Approval to Treat Type I Allergic Reactions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
